{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:40:23Z","timestamp":1774330823493,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T00:00:00Z","timestamp":1555459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00280-019-03842-1","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T16:41:01Z","timestamp":1555519261000},"page":"521-526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha"],"prefix":"10.1007","volume":"84","author":[{"given":"Faruk","family":"Tas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayhan","family":"Erturk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,17]]},"reference":[{"key":"3842_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"3842_CR2","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinell N et al (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 19:3622\u20133634","journal-title":"J Clin Oncol"},{"key":"3842_CR3","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199\u20136206","journal-title":"J Clin Oncol"},{"key":"3842_CR4","unstructured":"Hauschild A. Adjuvant melanoma therapy: European perspective. \n                    https:\/\/rvmais.com.br\/simposiomelanoma\/aulas\/26\/1630-1700-Axel%20Hauschild.pdf\n                    \n                  . Accessed 2 Mar 2019"},{"key":"3842_CR5","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cutaneous melanoma. Version 1.2019-November 1, 2018"},{"key":"3842_CR6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1385\/MO:23:4:471","volume":"23","author":"F Tas","year":"2006","unstructured":"Tas F, Kurul S, Camlica H, Topuz E (2006) Intermediate dose interferon alpha in adjuvant treatment for high risk melanoma: a single institution\u2019s experience. Med Oncol 23:471\u2013478","journal-title":"Med Oncol"},{"key":"3842_CR7","first-page":"24","volume":"3","author":"P Bhatia","year":"2015","unstructured":"Bhatia P, Friedlander P, Zakaria EA, Kandil E (2015) Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research. Ann Transl Med 3:24","journal-title":"Ann Transl Med"},{"key":"3842_CR8","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1186\/s12885-017-3529-5","volume":"17","author":"MV Heppt","year":"2017","unstructured":"Heppt MV, Siepmann T, Engel J, Schubert-Fritschle G, Eckel R, Mirlach L et al (2017) Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. BMC Cancer 17:536","journal-title":"BMC Cancer"},{"key":"3842_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/bjd.12939","volume":"171","author":"M Picard","year":"2014","unstructured":"Picard M, Dang NP, D\u2019Incan M, Mansard S, Dechelotte P, Pereira B et al (2014) Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection. Br J Dermatol 171:108\u2013114","journal-title":"Br J Dermatol"},{"key":"3842_CR10","doi-asserted-by":"publisher","first-page":"e86194","DOI":"10.1371\/journal.pone.0086194","volume":"9","author":"D Meckbach","year":"2014","unstructured":"Meckbach D, Bauer J, Pflugfelder A, Meier F, Busch C, Eigentler TK et al (2014) Survival according to BRAF-V600 tumor mutation\u2014an analysis of 437 patients with primary melanoma. PloS One 9:e86194","journal-title":"PloS One"},{"key":"3842_CR11","doi-asserted-by":"publisher","first-page":"djv435","DOI":"10.1093\/jnci\/djv435","volume":"108","author":"F Sabbatino","year":"2016","unstructured":"Sabbatino F, Wang Y, Scognamiglio G, Favoino E, Feldman SA, Villani V et al (2016) Antitumor activity of BRAF inhibitor and IFN\u03b1 combination 1 in BRAF mutant melanoma. J Natl Cancer Inst 108:djv435","journal-title":"J Natl Cancer Inst"},{"key":"3842_CR12","doi-asserted-by":"publisher","first-page":"djv432","DOI":"10.1093\/jnci\/djv432","volume":"108","author":"D Davar","year":"2016","unstructured":"Davar D, Fuchs SY, Kirkwood JM (2016) BRAF inhibitors and IFN\u03b1: plus, minus, or indeterminate? J Natl Cancer Inst 108:djv432","journal-title":"J Natl Cancer Inst"},{"key":"3842_CR13","doi-asserted-by":"publisher","first-page":"486391","DOI":"10.1155\/2015\/486391","volume":"2015","author":"HZ Kimbrell","year":"2015","unstructured":"Kimbrell HZ, Sholl AB, Ratnayaka S, Japa S, Lacey M, Carpio G et al (2015) BRAF testing in multifocal papillary thyroid carcinoma. Biomed Res Int 2015:486391","journal-title":"Biomed Res Int"},{"issue":"Suppl","key":"3842_CR14","doi-asserted-by":"publisher","first-page":"abstr 9047","DOI":"10.1200\/jco.2015.33.15_suppl.9047","volume":"33","author":"X Wang","year":"2015","unstructured":"Wang X, Mao LL, Si L, Chi Z, Cui C, Sheng XN (2015) Efficacy of high-dose adjuvant interferon therapy in high-risk melanoma harboring gene mutations. J Clin Oncol 33(Suppl):abstr 9047","journal-title":"J Clin Oncol"},{"key":"3842_CR15","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1158\/1078-0432.CCR-06-1387","volume":"13","author":"W Wang","year":"2007","unstructured":"Wang W, Edington HD, Rao UN, Jukic DM, Land SR, Ferrone S et al (2007) Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res 13:1523\u20131531","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03842-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03842-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03842-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T23:06:31Z","timestamp":1586991991000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03842-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,17]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["3842"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03842-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,17]]},"assertion":[{"value":"8 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study. The study was reviewed and approved by our local ethical committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All the procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}